Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Among authors: bettelheim p. Leukemia. 1998 Jul;12(7):1049-55. doi: 10.1038/sj.leu.2401066. Leukemia. 1998. PMID: 9665189 Clinical Trial.
High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B, et al. Hiddemann W, et al. Among authors: bettelheim p. Semin Hematol. 1991 Jul;28(3 Suppl 4):35-8. Semin Hematol. 1991. PMID: 1780750 Clinical Trial. No abstract available.
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B, et al. Hiddemann W, et al. Among authors: bettelheim p. Leuk Lymphoma. 1993;10 Suppl:133-7. doi: 10.3109/10428199309149125. Leuk Lymphoma. 1993. PMID: 8481662 Clinical Trial.
Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS.
Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, Della Porta MG, Ireland R, Johansson U, Matarraz S, Ogata K, Orfao A, Preijers F, Psarra K, Subirá D, Valent P, van der Velden VH, Wells D, Westers TM, Kern W, Béné MC. Porwit A, et al. Among authors: bettelheim p. Leukemia. 2014 Sep;28(9):1793-8. doi: 10.1038/leu.2014.191. Epub 2014 Jun 12. Leukemia. 2014. PMID: 24919805
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.
Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, Wells DA, Zettl F, Béné MC, van de Loosdrecht AA. Westers TM, et al. Among authors: bettelheim p. Leukemia. 2012 Jul;26(7):1730-41. doi: 10.1038/leu.2012.30. Epub 2012 Feb 6. Leukemia. 2012. PMID: 22307178
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10.
Béné MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, Lacombe F, Lemez P, Marinov I, Matutes E, Maynadié M, Oelschlagel U, Orfao A, Schabath R, Solenthaler M, Tschurtschenthaler G, Vladareanu AM, Zini G, Faure GC, Porwit A. Béné MC, et al. Among authors: bettelheim p. Leukemia. 2011 Apr;25(4):567-74. doi: 10.1038/leu.2010.312. Epub 2011 Jan 21. Leukemia. 2011. PMID: 21252983 Review.
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.
Eisenwort G, Sadovnik I, Keller A, Ivanov D, Peter B, Berger D, Stefanzl G, Bauer K, Slavnitsch K, Greiner G, Gleixner KV, Sperr WR, Willmann M, Sill H, Bettelheim P, Geissler K, Deininger M, Rülicke T, Valent P. Eisenwort G, et al. Among authors: bettelheim p. Leukemia. 2021 Nov;35(11):3176-3187. doi: 10.1038/s41375-021-01227-z. Epub 2021 Mar 30. Leukemia. 2021. PMID: 33785864 Free PMC article.
Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, Sperr WR, Bettelheim P, Akin C, Bauer K, George TI, Hadzijusufovic E, Wolf D, Gotlib J, Mahon FX, Metcalfe DD, Horny HP, Arock M. Valent P, et al. Among authors: bettelheim p. Leukemia. 2017 Apr;31(4):788-797. doi: 10.1038/leu.2017.15. Epub 2017 Jan 16. Leukemia. 2017. PMID: 28090091 Free PMC article. Review.
160 results